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Abstract
Introduction: The diagnostic efficacy of somatostatin receptor scintigraphy labeling with 111 indium in the
localization of tumors has been assessed in a limited number of patients with contradictory outcomes. Here, we
describe the case of a patient with an ectopic adrenocorticotropic hormone-producing bronchial carcinoid tumor
diagnosed preoperatively using technetium-99m-labeled octreotide acetate scintigraphy.
Case presentation: A 29-year-old Asian man presented to our hospital with the typical clinical features of
Cushing’s syndrome, which he had had for a duration of 18 months. The results of a biochemical evaluation
revealed he had adrenocorticotropic hormone-dependent Cushing’s syndrome. The results of a spiral abdominal
computed tomography scan showed he had bilateral adrenal hypertrophy. A magnetic resonance image of the
patient’s brain showed he had a normal hypophysis. Whole body technetium-99m-labeled octreotide acetate
scintigraphy was performed to check for the presence of an ectopic adrenocorticotropic hormone-producing
tumor. The scan results showed a small focal increase in uptake in the lower lobe of our patient’s right lung, just
above his diaphragm. A spiral chest computed tomography scan also revealed a small non-specific lesion in the
same region. A transthoracic biopsy was then performed. Pathological evaluation confirmed the diagnosis of a
carcinoid tumor, of the adrenocorticotropic hormone-producing type. After surgical removal, the patient’s
symptoms resolved and significant clinical improvement was achieved.
Conclusions: This case report shows that technetium-99m-labeled octreotide acetate scintigraphy can effectively
detect an ectopic adrenocorticotropic hormone-producing bronchial carcinoid.
Introduction
The ectopic secretion of adrenocorticotropic hormone
(ACTH) from nonpituitary tumors causes approximately
10% cases of Cushing’ss y n d r o m e[ 1 ] .I ns o m ep a t i e n t s ,
where the presence of an ectopic tumor has been con-
sidered as the cause of Cushing’s syndrome, localization
of the tumor has been difficult using modalities such as
computed tomography (CT) and magnetic resonance
imaging (MRI) of the patient’s chest and abdomen,
leaving palliative chemical or surgical adrenalectomy as
the available treatment options [2].
Somatostatin receptor scintigraphy (SRS) using 111
indium (In)-pentetreotide and 18F-fluorodeoxyglucose
positron emission tomography (FDG-PET) are the func-
tional techniques currently used to detect ectopic
ACTH-secreting lesions. However, the diagnostic effi-
cacy of SRS labeling with 111In in the localization of
such tumors has only been assessed in a limited number
of patients, with contradictory outcomes [3].
W ed e s c r i b eac a s eo fap a t i e n tw i t ha ne c t o p i c
ACTH-producing bronchial carcinoid tumor diagnosed
preoperatively using technetium-99m-labeled octreotide
acetate scintigraphy.
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A 29-year-old Asian man presented to our hospital with
upper and lower extremity weakness, significant weight
gain (20 kg over 18 months), dyspnea, insomnia, early-
morning awakening, psychiatric symptoms (illusions,
impaired concentration and memory, inappropriate
laughter and crying attacks), and erectile dysfunction.
Physical examination revealed the typical clinical fea-
tures of Cushing’s syndrome: hypotension, moon face,
buffalo hump, multiple purple striae on the flanks, prox-
imal myopathy and oral candidiasis. He was admitted to
our hospital with an initial diagnosis of hypercortisolism.
Biochemical test results confirmed the diagnosis and
revealed that he had elevated serum cortisol (8 a.m.)
and ACTH levels on multiple samplings. Dexametha-
sone suppression test results were positive on two con-
secutive samplings. His urine cortisol level was elevated,
but his vanillylmandelic acid and metanephrine levels
were normal. Other laboratory tests were noncontribu-
tory to the diagnosis.
An MRI scan of his brain found no pituitary defects,
but a spiral abdominal CT scan revealed bilateral adre-
nal hyperplasia. The clinical and imaging findings raised
suspicion of an ACTH-producing tumor. A broncho-
scopy and alveolar lavage was performed to investigate
the patient’s lungs, but no bronchial lesion was found.
Technetium-99m-labeled octreotide acetate scintigra-
phy was performed in the whole body planar (Figures 1
and 2) and single photon emission CT mode (Figure 3),
3 hours after the injection of 555MBq (15mCi) techne-
tium-99m-labeled octreotide acetate. The scan demon-
strated a focal uptake in the lower lobe of the patient’s
right lung, just above his diaphragm, which was highly
suggestive of an ACTH-producing bronchial tumor.
Corresponding transverse images from a chest CT scan
showed a well-defined mass about 22 mm in diameter in
the lower lobe of the patient’s right lung (Figure 4).
A transthoracic biopsy was performed and histopatho-
logical evaluation established the diagnosis of a carci-
noid tumor of the ectopic ACTH-producing type. After
removal of the mass, the patient’s condition improved
significantly. His clinical symptoms diminished and the
results of biochemical tests returned to normal ranges.
Discussion
Ectopic ACTH-producing tumors occur in approxi-
mately 10% of cases of patients with Cushing’ss y n -
drome. Although a biochemical diagnosis of Cushing’s
syndrome is easily achieved, localization of the tumor is
more difficult [1,3]. Cushing’s disease is the cause of
Cushing’s syndrome in 70% of cases. A bronchial
Figure 1 Technetium-99m-labeled octreotide acetate
scintigraphy in the whole body planar view. This was performed
3 hours after injection of 15mCi technetium-99m-labeled octreotide
acetate. There is a focal uptake in the lower lobe of our patient’s
right lung, just above his diaphragm, highly suggestive of an
adrenocorticotropic hormone (ACTH)-producing bronchial tumor.
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lesion responsible in most cases [4,5]. Carcinoid tumors
are malignant neoplasms originating from neuroendo-
crine cells [6]. To investigate the exact location of such
tumors multiple imaging modalities are required, and at
present no single modality can pinpoint the location of
a suspected lesion [5,7]. The diagnostic utility of In-111
technetium-99m-labeled octreotide acetate scintigraphy
in patients with suspected lesions has been debated.
Some believe that it is not helpful [5], whereas others
have reported radionuclide imaging to be a useful diag-
nostic tool [3].
From a literature review, we found limited studies
have addressed the use of an octreotide compound with
technetium labeling. Although In-111-labeled octreotide
scintigraphy has been shown to be a helpful tool for the
diagnosis of somatostatin-expressing tumors, and this
method has been broadly used, it has several shortcom-
ings such as high radiation dose, high cost and limited
Figure 2 Technetium-99m-labeled octreotide acetate
scintigraphy in spot abdominal view. This was performed 3 hours
after injection of 15mCi technetium-99m-labeled octreotide acetate.
There is a focal uptake in the lower lobe of our patient’s right lung, just
above his diaphragm, highly suggestive of an adrenocorticotropic
hormone (ACTH)-producing bronchial tumor.
Figure 3 Technetium-99m-labeled octreotide acetate scintigraphy performed in single photon emission computed tomography mode.
This was conducted 3 hours after injection of 15mCi technetium-99m-labeled octreotide acetate. The scan demonstrated a focal uptake in the
lower lobe of our patient’s right lung, just above his diaphragm, highly suggestive of an adrenocorticotropic hormone (ACTH)-producing
bronchial tumor.
Figure 4 Corresponding transverse images of a chest
computed tomography scan showing a well-defined mass
about 22 mm in the lower lobe of the patient’s right lung.
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pounds have been labeled with Tc-99m.
In one study, the diagnostic outcomes of In-111
octreotide scintigraphy and Tc-99m Hynic Toc/Tate
scintigraphy in 24 patients with different pathologies
including two cases of ectopic Cushing’s disease, were
found to be identical [8].
In another investigation, the clinical value of tomo-
graphic technetium-99m-labeled octreotide acetate scin-
tigraphy was compared with
18F-FDG dual-head
coincidence imaging (DHC) of 44 patients with sus-
pected lung tumors [9]. The sensitivity, specificity, posi-
tive predictive value, and negative predictive value of
technetium-99m-labeled octreotide acetate scintigraphy
were 100%, 75.7%, 90.1%, and 100%, respectively; and
for
18F-FDG DHC the values were 100%, 46.1%, 83.8%,
and 100%, respectively [9]. This comparison demon-
strated that tomographic technetium-99m-labeled
octreotide acetate scintigraphy had high sensitivity for
distant metastases but lower sensitivity for the detection
of hilar and mediastinal lymph node metastasis as com-
pared with
18F-FDG DHC coincidence PET [9].
Our case report shows the usefulness of technetium-
99m-labeled octreotide acetate scintigraphy in the locali-
zation of ectopic ACTH-secreting tumors in patients
biochemically and clinically diagnosed with Cushing’s
syndrome. However, further well-designed studies to
evaluate its efficacy are required.
Conclusions
Our case report shows that technetium-99m-labeled
octreotide acetate scintigraphy can effectively detect an
ectopic ACTH-producing bronchial carcinoid.
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